Novel bergamot oil nanospanlastics combined with PUVB therapy as a clinically translatable approach for vitiligo treatment

  • Mai Shaaban
  • Maha NasrEmail author
  • Abeer Attia Tawfik
  • Maha Fadel
  • Omaima Sammour
Original Article


The impact of nanomedicine has grown in the current decade; however, only very few clinical translational attempts have been realized. Therefore in the present study, we hypothesized that bergamot oil, a psoralen-containing oil, would produce an optimized melanogenic effect in the clinical treatment of vitiligo when loaded within an elastic nanocarrier (spanlastics) and combined with PUVB for activation of psoralens. Spanlastics were prepared and characterized for particle size, physical stability, in vitro release, thermal behavior, deformability, morphology, and in vitro photostability. The efficacy of the selected formula was tested histopathologically on rat skin and clinically translated in patients suffering from vitiligo. Results revealed that the spanlastics were of reasonable nanosize, deformable, and provided sustained release of bergamot oil. The incorporation of bergamot oil within spanlastics improved its photostability and its photodynamic activity. Spanlastics exhibited promising clinical results in terms of extent and onset of repigmentation in vitiligo patients. Therefore, it can be concluded that spanlastics can be introduced as a promising nanotreatment modality for vitiligo.


Spanlastics Bergamot oil Phototherapy Vitiligo 


Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest. The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors.

Ethical approval

All institutional and national guidelines for the use and care of laboratory animals were followed. All clinical procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.


  1. 1.
    de Menezes AF, Oliveira de Carvalho F, Barreto RS, de Santana Silva B, Shanmugam S, Gurgel RQ, et al. Pharmacologic treatment of vitiligo in children and adolescents: a systematic review. Pediatr Dermatol. 2017;34:13–24.CrossRefGoogle Scholar
  2. 2.
    El-Mofty M, Mostafa WZ, Bosseila M, Youssef R, Esmat S, El Ramly A, et al. A large scale analytical study on efficacy of different photo(chemo)therapeutic modalities in the treatment of psoriasis, vitiligo and mycosis fungoides. Dermatol Ther. 2010;23:428–34.CrossRefGoogle Scholar
  3. 3.
    Serrano-Pérez JJ, Merchan M, Serrano-Andres L. Photoreactivity of furocoumarins and DNA in PUVA therapy: formation of psoralen– thymine adducts. J Phys Chem B. 2008;112:14002–10.CrossRefGoogle Scholar
  4. 4.
    Bansal S, Sahoo B, Garg V. Psoralen–narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed. 2013;29:311–7.CrossRefGoogle Scholar
  5. 5.
    Powers MC, Lim HW. Phototherapy in vitiligo. In: Handog EB, Enriquez-Macarayo MJ, editors. Melasma and vitiligo in brown skin. 1st ed: Springer; 2017. p. 311–25.Google Scholar
  6. 6.
    Sapam R, Agrawal S, Dhali TK. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study. Int J Dermatol. 2012;51:1107–15.CrossRefGoogle Scholar
  7. 7.
    Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638–42.CrossRefGoogle Scholar
  8. 8.
    Roelandts R. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed. 2003;19:1–4.CrossRefGoogle Scholar
  9. 9.
    Pacifico A, Leone G. Photo(chemo)therapy for vitiligo. Photodermatol Photoimmunol Photomed. 2011;27:261–77.CrossRefGoogle Scholar
  10. 10.
    Kinley JS, Moan J, Dall’Aqua F, Young AR. Quantitative assessment of epidermal melanogenesis in C3H/Tif hr/hr mice treated with topical furocoumarins and UVA radiation. J Invest Dermatol. 1994;103:97–103.CrossRefGoogle Scholar
  11. 11.
    Zaynoun S, Johnson B, Frain-Bell W. A study of oil of bergamot and its importance as a phototoxic agent. Contact Dermatitis. 1977;3:225–39.CrossRefGoogle Scholar
  12. 12.
    Hatem S, Nasr M, Moftah NH, Ragai MH, Geneidi AS, Elkheshen SA. Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: design, characterization and clinical appraisal. Eur J Pharm Sci. 2018;122:246–53.CrossRefGoogle Scholar
  13. 13.
    Hatem S, Nasr M, Elkheshen SA, Geneidi AS. Recent advances in antioxidant cosmeceutical topical delivery. Curr Drug Deliv. 2018;Epub ahead of print;15:953–64.CrossRefGoogle Scholar
  14. 14.
    Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol. 2015;81:457–63.CrossRefGoogle Scholar
  15. 15.
    Fadel M, Kassab K, Abd El Fadeel DA, Nasr M, El Ghoubary NM. Comparative enhancement of curcumin cytotoxic photodynamic activity by nanoliposomes and gold nanoparticles with pharmacological appraisal in HepG2 cancer cells and Erlich solid tumor model. Drug Dev Ind Pharm. 2018;44:1809–16.CrossRefGoogle Scholar
  16. 16.
    Fadel M, Samy N, Nasr M, Alyoussef AA. Topical colloidal indocyanine green-mediated photodynamic therapy for treatment of basal cell carcinoma. Pharm Dev Technol. 2017;22:545–50.CrossRefGoogle Scholar
  17. 17.
    Bsieso EA, Nasr M, Moftah NH, Sammour OA. Abd El Gawad NA. Could nanovesicles containing a penetration enhancer clinically improve the therapeutic outcome in skin fungal diseases? Nanomedicine (Lond). 2015;10:2017–31.CrossRefGoogle Scholar
  18. 18.
    Kakkar S, Kaur IP. Spanlastics—a novel nanovesicular carrier system for ocular delivery. Int J Pharm. 2011;413:202–10.CrossRefGoogle Scholar
  19. 19.
    Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Int J Pharm. 2015;483:77–88.CrossRefGoogle Scholar
  20. 20.
    Kakkar S, Kaur IP. A novel nanovesicular carrier system to deliver drug topically. Pharm Dev Technol. 2013;18:673–85.CrossRefGoogle Scholar
  21. 21.
    Ashraf O, Nasr M, Nebsen M, Said AMA, Sammour O. In vitro stabilization and in vivo improvement of ocular pharmacokinetics of the multitherapeutic agent baicalin: delineating the most suitable vesicular systems. Int J Pharm. 2018;539:83–94.CrossRefGoogle Scholar
  22. 22.
    Agiba AM, Nasr M, Abdel-Hamid S, Eldin AB, Geneidi AS. Enhancing the intestinal permeation of the chondroprotective nutraceuticals glucosamine sulphate and chondroitin sulphate using conventional and modified liposomes. Curr Drug Deliv. 2018;15:907–16.CrossRefGoogle Scholar
  23. 23.
    Barakat SS, Nasr M, Ahmed RF, Badawy SS, Mansour S. Intranasally administered in situ gelling nanocomposite system of dimenhydrinate: preparation, characterization and pharmacodynamic applicability in chemotherapy emesis model. Sci Rep. 2017;7:9910.CrossRefGoogle Scholar
  24. 24.
    Mouez MA, Nasr M, Abdel-Mottaleb M, Geneidi AS, Mansour S. Composite chitosan-transfersomal vesicles for improved transnasal permeation and bioavailability of verapamil. Int J Biol Macromol. 2016;93:591–9.CrossRefGoogle Scholar
  25. 25.
    Bseiso EA, Nasr M, Sammour OA, Abd El Gawad NA. Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis. Drug Deliv. 2016;23:2813–9.CrossRefGoogle Scholar
  26. 26.
    Nasr M, Mansour S, Mortada ND, Elshamy AA. Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. J Microencapsul. 2008;25:499–512.CrossRefGoogle Scholar
  27. 27.
    Abdelgawad R, Nasr M, Moftah NH, Hamza MY. Phospholipid membrane tubulation using ceramide doping “cerosomes”: characterization and clinical application in psoriasis treatment. Eur J Pharm Sci. 2017;101:258–68.CrossRefGoogle Scholar
  28. 28.
    Lima AM, Pizzol CD, Monteiro FB, Creczynski-Pasa TB, Andrade GP, Ribeiro AO, et al. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J Photochem Photobiol B. 2013;125:146–54.CrossRefGoogle Scholar
  29. 29.
    Weiss-Angeli V, Poletto FS, Zancan LR, Baldasso F, Pohlmann AR, Guterres SS. Nanocapsules of octyl methoxycinnamate containing quercetin delayed the photodegradation of both components under ultraviolet A radiation. J Biomed Nanotechnol. 2008;4:80–9.Google Scholar
  30. 30.
    Nasr M, Taha I, Hathout RM. Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route. Drug Deliv. 2013;20:311–8.CrossRefGoogle Scholar
  31. 31.
    El Mofty M, Mostafa W, Esmat S, Youssef R, Azzam O, Hunter N, et al. Narrow band ultraviolet B 311 nm in the treatment of vitiligo: two right–left comparison studies. Photodermatol Photoimmunol Photomed. 2006;22:6–11.CrossRefGoogle Scholar
  32. 32.
    El-Ridy MS, Badawi AA, Safar MM, Mohsen AM. Niosomes as a novel pharmaceutical formulation encapsulating the hepatoprotective drug silymarin. Int J Pharm Pharm Sci. 2012;4:549–59.Google Scholar
  33. 33.
    Sezgin-Bayindir Z, Yuksel N. Investigation of formulation variables and excipient interaction on the production of niosomes. AAPS PharmSciTech. 2012;13:826–35.CrossRefGoogle Scholar
  34. 34.
    Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm. 1994;105:1–6.CrossRefGoogle Scholar
  35. 35.
    Khurshid K, Haroon TS, Hussain I, Pal SS, Jahanqir M, Zaman T. Psoralen–ultraviolet A therapy vs. psoralen–ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with Fitzpatrick skin type IV. Int J Dermatol. 2000;39:865–7.CrossRefGoogle Scholar
  36. 36.
    Averbeck D. Recent advances in psoralen phototoxicity mechanism. Photochem Photobiol. 1989;50:859–82.CrossRefGoogle Scholar
  37. 37.
    Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005;59:485–90.CrossRefGoogle Scholar
  38. 38.
    Salama HA, Mahmoud AA, Kamel AO, Abdel Hady M, Awad GA. Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res. 2012;22:336–45.CrossRefGoogle Scholar
  39. 39.
    Soliman SM, Abdelmalak NS, El-Gazayerly ON, Abdelaziz N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 23 factorial design and in vivo evaluation in rabbits. Drug Deliv. 2016;23:1608–22.CrossRefGoogle Scholar
  40. 40.
    Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Oh DH, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm. 2009;377:1–8.CrossRefGoogle Scholar
  41. 41.
    Lee EH, Kim A, Oh YK, Kim CK. Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials. 2005;26:205–10.CrossRefGoogle Scholar
  42. 42.
    Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010;99:2049–60.CrossRefGoogle Scholar
  43. 43.
    Detoni CB, Cabral-Albuquerque EC, Hohlemweger SV, Sampaio C, Barros TF, Velozo ES. Essential oil from Zanthoxylum tingoassuiba loaded into multilamellar liposomes useful as antimicrobial agents. J Microencapsul. 2009;26:684–91.CrossRefGoogle Scholar
  44. 44.
    Eid RK, Essa EA, El Maghraby GM. Essential oils in niosomes for enhanced transdermal delivery of felodipine. Pharm Dev Technol. 2018.Google Scholar
  45. 45.
    Sánchez-González L, Chafer M, Chiralt A, Gonzalez-Martinez C. Physical properties of edible chitosan films containing bergamot essential oil and their inhibitory action on Penicillium italicum. Carbohydr Polym. 2010;82:277–83.CrossRefGoogle Scholar
  46. 46.
    de Berker DA, Sakuntabhai A, Diffey BL, Matthews JN, Farr PM. Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis. J Am Acad Dermatol. 1997;36:577–81.CrossRefGoogle Scholar
  47. 47.
    Ortel B, Perl S, Kinaciyan T, Calzavara-Pinton PG, Honigsmann H. Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol. 1993;29:736–40.CrossRefGoogle Scholar
  48. 48.
    Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol. 2005;44:57–60.CrossRefGoogle Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutics and Industrial Pharmacy, Faculty of PharmacyAin Shams UniversityCairoEgypt
  2. 2.Dermatology and Laser Dermatology Unit, Department of Medical Applications of Laser, National Institute of Laser Enhanced SciencesCairo UniversityCairoEgypt
  3. 3.Pharmaceutical Technology Unit, Department of Medical Applications of Laser, National Institute of Laser Enhanced SciencesCairo UniversityCairoEgypt

Personalised recommendations